Just 20% of firms with 200 or more workers said they covered GLP-1 drugs for weight loss, according to the Peterson-KFF Health System Tracker.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Science Corp., a brain-implant startup developing a device that can enable blind people to see again, just raised $230 million from investors.
As the GLP-1 drugs like Wegovy and Zepbound have proven, there’s a lot of money to be made in helping people look good and feel good.
The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment anito-cel.
Just last week, the agency rejected Moderna’s initial application, citing flaws in the company’s research design.
Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.
The proliferation of cheaper generic drugs and more competition has already begun to bring down prices on weight-loss treatments.
UNH has struggled in recent years on account of rising medical costs and lower-than-expected Medicare Advantage reimbursements.
The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.
Just last year, the FDA sent a warning letter to wellness wearable firm Whoop after it rolled out a feature to check users’ blood pressure.
US firms are also staring down a multi-billion dollar patent cliff of their own, prompting a yearslong buying spree.
While 2025’s IPO boom is likely being enjoyed by Wall Street’s investment bankers, it may be even better news for private equity.
The next few years of projected revenues in the pharma space have more holes in them than industry CEOs’ favorite golf courses.
The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.
The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.
Earlier this month, Exact reported a record $851 million in third-quarter revenue, which included $666 million from its screening business.